



UNIVERSITÉ DE GENEVE

Licensing Opportunity

UNIVERSITY OF GENEVA



520-A334: Highly sulfated proteoglycans with potential cardiovascular protective effects and anti-tissue remodeling inflammation activities

Invention

Heparan sulfate proteoglycans (HSPG) in extravascular tissues such as ovary are assumed to control hormone-dependent tissue remodeling via proteolysis and acute local inflammation reactions.

The team of Dr. A. De Agostini at the Geneva Hospital in collaboration with Prof. R. Linhardt at the Raenssler Institute have purified HSPGs from human follicular fluid, determined their exact compositions and characterized their biological properties in vitro.

Applications

The present technology provide a new source and compositions of HSPG that could be used to

- Reduce thrombotic risks, specifically in post-menopausal women as well as in men.
- Control tissue remodeling and cell migration in certain cancers.
- Ascertain follicular rupture at ovulation and treat infertility.

Stage of developments

- A methodology to purify HSPG from human follicular fluids.
- A structural characterization of purified HSPGs.
- A functional analysis (e.g. anticoagulant activity) and identification of protein effectors that physiologically interact with purified HSPGs.

Collaboration and licensing opportunity

The University of Geneva is seeking a commercial partner:

- to sponsor research and development of the therapeutic use of HSPGs
- to license US pending patents (U) describing the use of new HSPG compositions.



Université de Genève
24, Rue Général-Dufour
1211 Geneva 4
Switzerland

Contact

Dr. Olivier Deloche, M.Law
Phone: +41(22) 379 0355
email:olivier.deloche@unige.ch